Literature DB >> 23928023

Association of norB overexpression and fluoroquinolone resistance in clinical isolates of Staphylococcus aureus from Korea.

Yee Gyung Kwak1, Que Chi Truong-Bolduc, Hong Bin Kim, Kyoung-Ho Song, Eu Suk Kim, David C Hooper.   

Abstract

OBJECTIVES: Although the prevalence of fluoroquinolone resistance among methicillin-resistant Staphylococcus aureus (MRSA) is known to be higher than in methicillin-susceptible S. aureus (MSSA), the reasons have never been identified.
METHODS: We randomly selected 115 isolates of S. aureus collected from 10 different hospitals in Korea between June 2009 and May 2011. To investigate the difference in fluoroquinolone resistance mechanisms between MRSA and MSSA, we evaluated gyrA and parC mutations and the relative expression of the multidrug efflux pump genes norA, norB and norC.
RESULTS: All 62 ciprofloxacin-resistant S. aureus had either gyrA or parC mutations. The S84L mutation of gyrA (59/62, 95.2%) and the S80F mutation of parC (61/62, 98.4%) were the most common. Fifty-eight (93.6%) strains had both the S84L mutation of gyrA and the S80F mutation of parC. Among the 115 isolates, norB overexpression was the most common, occurring in 49 (42.6%) strains. There were only two (1.7%) strains with norA overexpression and none with norC overexpression. Strains overexpressing norB were more common among ciprofloxacin-resistant S. aureus (33/62, 53.2%) than ciprofloxacin-susceptible S. aureus (16/53, 30.2%) (P = 0.013). When we analysed 62 ciprofloxacin-resistant S. aureus strains, those overexpressing norB were more common in ciprofloxacin-resistant MRSA (28/46, 60.9%) than in ciprofloxacin-resistant MSSA (5/16, 31.3%) (P = 0.041).
CONCLUSIONS: Increased expression of norB can be a factor that contributes to ciprofloxacin resistance in MRSA strains.

Entities:  

Keywords:  S. aureus; ciprofloxacin; efflux pumps

Mesh:

Substances:

Year:  2013        PMID: 23928023      PMCID: PMC3820107          DOI: 10.1093/jac/dkt286

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  32 in total

1.  Efflux-related resistance to norfloxacin, dyes, and biocides in bloodstream isolates of Staphylococcus aureus.

Authors:  Carmen E DeMarco; Laurel A Cushing; Emmanuel Frempong-Manso; Susan M Seo; Tinevimbo A A Jaravaza; Glenn W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

2.  NorC, a new efflux pump regulated by MgrA of Staphylococcus aureus.

Authors:  Que Chi Truong-Bolduc; Jacob Strahilevitz; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

3.  Sequence analysis of the variable number tandem repeat in Staphylococcus aureus protein A gene: spa typing.

Authors:  Barun Mathema; Jose Mediavilla; Barry N Kreiswirth
Journal:  Methods Mol Biol       Date:  2008

4.  Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates.

Authors:  F J Schmitz; A C Fluit; S Brisse; J Verhoef; K Köhrer; D Milatovic
Journal:  FEMS Immunol Med Microbiol       Date:  1999-12

5.  Assignment of Staphylococcus isolates to groups by spa typing, SmaI macrorestriction analysis, and multilocus sequence typing.

Authors:  B Strommenger; C Kettlitz; T Weniger; D Harmsen; A W Friedrich; W Witte
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

6.  Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002.

Authors:  Norihisa Noguchi; Takeshi Okihara; Yuta Namiki; Yuichi Kumaki; Yoshihiro Yamanaka; Masaharu Koyama; Kazunori Wakasugi; Masanori Sasatsu
Journal:  Int J Antimicrob Agents       Date:  2005-05       Impact factor: 5.283

7.  Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998.

Authors:  T S Naimi; K H LeDell; D J Boxrud; A V Groom; C D Steward; S K Johnson; J M Besser; C O'Boyle; R N Danila; J E Cheek; M T Osterholm; K A Moore; K E Smith
Journal:  Clin Infect Dis       Date:  2001-09-05       Impact factor: 9.079

8.  Development of resistance to ciprofloxacin, rifampin, and mupirocin in methicillin-susceptible and -resistant Staphylococcus aureus isolates.

Authors:  F J Schmitz; A C Fluit; D Hafner; A Beeck; M Perdikouli; M Boos; S Scheuring; J Verhoef; K Köhrer; C Von Eiff
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

9.  Emergence of quinolone resistance among clinical isolates of methicillin-resistant Staphylococcus aureus in Ontario, Canada.

Authors:  N Harnett; S Brown; C Krishnan
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

10.  A survey of community-associated methicillin-resistant Staphylococcus aureus in Korea.

Authors:  Eu Suk Kim; Jin Su Song; Hye Jin Lee; Pyoeng Gyun Choe; Kyung Hwa Park; Jae Hyun Cho; Wan Beom Park; Sung-Han Kim; Ji-Hwan Bang; Dong-Min Kim; Kyoung Un Park; Sue Shin; Mi Suk Lee; Hee Jung Choi; Nam Joong Kim; Eui-Chong Kim; Myoung-Don Oh; Hong Bin Kim; Kang Won Choe
Journal:  J Antimicrob Chemother       Date:  2007-09-20       Impact factor: 5.790

View more
  25 in total

1.  Prevalence of Enterotoxin Genes and spa Genotypes of Methicillin-resistant Staphylococcus aureus from a Tertiary Care Hospital in China.

Authors:  Yanmeng Li; Ruike Zhao; Xianfeng Zhang; Qingzhen Han; Xuefeng Qian; Guohao Gu; Jinfang Shi; Jie Xu
Journal:  J Clin Diagn Res       Date:  2015-05-01

2.  Transcriptional Regulator TetR21 Controls the Expression of the Staphylococcus aureus LmrS Efflux Pump.

Authors:  Q C Truong-Bolduc; Y Wang; C Chen; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

Review 3.  Clinical importance and epidemiology of quinolone resistance.

Authors:  Eu Suk Kim; David C Hooper
Journal:  Infect Chemother       Date:  2014-12-29

Review 4.  Multidrug efflux pumps in Staphylococcus aureus and their clinical implications.

Authors:  Soojin Jang
Journal:  J Microbiol       Date:  2016-01-05       Impact factor: 3.422

5.  Tet38 of Staphylococcus aureus Binds to Host Cell Receptor Complex CD36-Toll-Like Receptor 2 and Protects from Teichoic Acid Synthesis Inhibitors Tunicamycin and Congo Red.

Authors:  Q C Truong-Bolduc; Y Wang; D C Hooper
Journal:  Infect Immun       Date:  2019-06-20       Impact factor: 3.441

6.  Emergence and Within-Host Genetic Evolution of Methicillin-Resistant Staphylococcus aureus Resistant to Linezolid in a Cystic Fibrosis Patient.

Authors:  Caroline Rouard; Fabien Garnier; Jeremy Leraut; Margaux Lepainteur; Lalaina Rahajamananav; Jeanne Languepin; Marie-Cécile Ploy; Nadège Bourgeois-Nicolaos; Florence Doucet-Populaire
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

7.  Role of the Tet38 Efflux Pump in Staphylococcus aureus Internalization and Survival in Epithelial Cells.

Authors:  Q C Truong-Bolduc; G R Bolduc; H Medeiros; J M Vyas; Y Wang; D C Hooper
Journal:  Infect Immun       Date:  2015-08-31       Impact factor: 3.441

8.  The Whole Is Bigger than the Sum of Its Parts: Drug Transport in the Context of Two Membranes with Active Efflux.

Authors:  Valentin V Rybenkov; Helen I Zgurskaya; Chhandosee Ganguly; Inga V Leus; Zhen Zhang; Mohammad Moniruzzaman
Journal:  Chem Rev       Date:  2021-02-17       Impact factor: 60.622

9.  Anti-hepatitis C virus drug simeprevir: a promising antimicrobial agent against MRSA.

Authors:  Yimin Li; Pengfei She; Lanlan Xu; Yaqian Liu; Shasha Liu; Zehao Li; Yifan Yang; Linhui Li; Zubair Hussain; Yong Wu
Journal:  Appl Microbiol Biotechnol       Date:  2022-03-26       Impact factor: 4.813

10.  Comparative Transcriptomic Analysis of Staphylococcus aureus Associated with Periprosthetic Joint Infection under in Vivo and in Vitro Conditions.

Authors:  Thao Le Masters; Stephen Johnson; Patricio R Jeraldo; Kerryl E Greenwood-Quaintance; Scott A Cunningham; Matthew P Abdel; Nicholas Chia; Robin Patel
Journal:  J Mol Diagn       Date:  2021-06-05       Impact factor: 5.341

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.